| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |